» Articles » PMID: 21586487

Grey Matter Volume in a Large Cohort of MS Patients: Relation to MRI Parameters and Disability

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2011 May 19
PMID 21586487
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although grey matter damage in multiple sclerosis is currently recognized, determinants of grey matter volume and its relationship with disability are not yet clear.

Objectives: The objectives of the study were to measure grey and white matter volumes across different disease phenotypes; identify MRI parameters associated with grey matter volume; and study grey and white matter volume as explanatory variables for clinical impairment.

Methods: This is a cross-sectional study in which MRI data of 95 clinically isolated syndrome, 657 relapsing-remitting, 125 secondary-progressive and 50 primary-progressive multiple sclerosis patients from three centres were acquired. Grey and white matter volumes were determined, together with T2 and T1 lesion volumes. Physical disability was assessed with the Expanded Disability Status Scale, cognitive impairment with the Paced Auditory Serial Addition Task. Data were analysed using multiple regression.

Results: Grey matter volume was lower in relapsing-remitting patients (mean [SD]: 0.80 [0.05] L) than in clinically isolated syndrome patients (0.82 [0.05] L), and even greater relative atrophy was found in secondary-progressive patients (0.77 [0.05] L). In contrast, white matter volume in secondary-progressive patients was comparable to that in relapsing-remitting patients. Grey matter volume was the strongest independent predictor of physical disability and cognitive impairment, and was associated with both T2 and T1 lesion volume.

Conclusions: Our findings show that grey matter volume is lower in secondary-progressive than in relapsing-remitting disease. Grey matter volume explained physical and cognitive impairment better than white matter volume, and is itself associated with T2 and T1 lesion volume.

Citing Articles

Neuroimaging markers and disability scales in multiple sclerosis: A systematic review and meta-analysis.

Mirmosayyeb O, Yazdan Panah M, Mokary Y, Mohammadi M, Moases Ghaffary E, Shaygannejad V PLoS One. 2024; 19(12):e0312421.

PMID: 39637162 PMC: 11620670. DOI: 10.1371/journal.pone.0312421.


Longitudinal network-based brain grey matter MRI measures are clinically relevant and sensitive to treatment effects in multiple sclerosis.

Colato E, Stutters J, Narayanan S, Arnold D, Chataway J, Wheeler-Kingshott C Brain Commun. 2024; 6(4):fcae234.

PMID: 39077376 PMC: 11285187. DOI: 10.1093/braincomms/fcae234.


Links between Neuroanatomy and Neurophysiology with Turning Performance in People with Multiple Sclerosis.

Swanson C, Fling B Sensors (Basel). 2023; 23(17).

PMID: 37688084 PMC: 10490793. DOI: 10.3390/s23177629.


Potential biological contributers to the sex difference in multiple sclerosis progression.

Alvarez-Sanchez N, Dunn S Front Immunol. 2023; 14:1175874.

PMID: 37122747 PMC: 10140530. DOI: 10.3389/fimmu.2023.1175874.


The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.

Gentile G, Mattiesing R, Brouwer I, van Schijndel R, Uitdehaag B, Twisk J Neuroimage Clin. 2023; 38:103397.

PMID: 37086648 PMC: 10300577. DOI: 10.1016/j.nicl.2023.103397.